Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)

Inclusion Criteria: * Body mass index (BMI) \>=18 to\<=37 kg/m\^2 * In general good health, except for HCV infection * Clinical diagnosis of chronic HCV infection exclusively GT3 (Panels A-D) or exclusively GT1a (Panels E-F), or exclusively GT2b (Panels G-H). * Must agree to follow the smoking restrictions defined by the CRU * Must agree to use an acceptable method of contraception during the study and for 90 days after the last dose of ruzasvir Exclusion Criteria: * Clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary or major neurological abnormalities or diseases * History of clinically significant hepatic disease, Gilbert's disease or biliary tract disease * History of cancer (malignancy) with the exception of adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix, or successfully-treated malignancies ≥10 years prior to screening * History of significant multiple and/or severe allergies or has had an anaphylactic reaction or significant intolerability to prescription or nonprescription drugs or food * Positive for hepatitis B or human immunodeficiency virus (HIV) * Major surgery or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to screening * Participated in another investigational trial within 4 weeks prior to the screening visit * QTc interval \>=470 msec (for males) or \>= 480 msec (for females) * Unable to refrain from or anticipates use of any medication (prescription and/or non-prescription) or herbal remedies beginning approximately 2 weeks prior to first study drug dose, throughout the trial until the post-trial visit * Consumes \>2 glasses of alcoholic beverages per day * Regular user (including "recreational use") of any illicit drugs or history of drug (including alcohol) abuse within approximately 12 months * Evidence or history of chronic hepatitis not caused by HCV * Previous treatment with other HCV NS5A inhibitors such as MK-8742, daclatasvir, or MK-8325 * Treatment with other HCV therapies such as the HCV protease * Evidence of advanced or decompensated liver disease; evidence of bridging fibrosis or higher grade fibrosis (Metavir score \>=3)